Ketamine for Veterans With Parkinson's Disease
Phase 2
80
about 4.2 years
40–80
1 site in CA
About this study
Researchers are testing if ketamine, given as an intravenous (IV) injection, can improve depression in Veterans with Parkinson's disease. The trial will also examine how ketamine affects neuroplasticity and inflammation in these individuals. It aims to determine if ketamine could be a useful treatment for Veterans with Parkinson's disease.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Ketamine
- 2.Take Remimazolam
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
ketamine (NMDA receptor antagonist; induces dissociative anesthesia and analgesia), remimazolam
injection, intravenous
Primary: Montgomery-Asberg Depression Rating Scale (MADRS)
Secondary: Enhanced Scale for the Assessment of Positive Symptoms for Parkinson's Disease (eSAPS- PD), Hamilton Anxiety Rating Scale (HAM-A), Hamilton Depression Rating Scale-7 (HAMD-7), Incidence, severity, and frequency of Adverse Events (AEs) including Treatment- Emergent AEs (TEAEs) and Serious AEs (SAEs), Montgomery-Asberg Depression Rating Scale (MADRS), Movement Disorder Society revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Patient- Reported Outcomes Measurement Information System (PROMIS®), Quality of Life in Neurological Disorders (Neuro-QoLTM)
Neurology